• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Altimmune Inc. (Amendment)

    2/14/24 11:36:18 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALT alert in real time by email
    SC 13G/A 1 c108110_sc13ga.htm

    CUSIP No. 02155H200

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 3)*

     

    Altimmune, Inc.
    (Name of Issuer)
     
    Common Stock
    (Title of Class of Securities)
     
    02155H200
    (CUSIP Number)
     
    December 31, 2023
    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

     

    o  Rule 13d-1(c)

     

    o  Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    (Continued on following page(s))

     

    CUSIP No. 02155H200

     

    13G Page 2 of 9  

     

    1. NAME OF REPORTING PERSONS  
         
      Nuveen Asset Management, LLC 27-4357327  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) o
        (b) o
         
    3. SEC USE ONLY  
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED  
    BY EACH REPORTING PERSON WITH:  
       
      5. SOLE VOTING POWER 6,679
           
      6. SHARED VOTING POWER 0
           
      7. SOLE DISPOSITIVE POWER 6,679
           
      8. SHARED DISPOSITIVE POWER 0
           
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
      6,679  
       
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES o
       
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
       
      0.01%  
       
    12. TYPE OF REPORTING PERSON
       
      IA  
     

    CUSIP No. 02155H200

     

    13G Page 3 of 9  

     

    1. NAME OF REPORTING PERSONS  
         
      TIAA-CREF Investment Management, LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) o
        (b) o
         
    3. SEC USE ONLY  
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED  
    BY EACH REPORTING PERSON WITH:  
       
      5. SOLE VOTING POWER 1,549,364
           
      6. SHARED VOTING POWER 0
           
      7. SOLE DISPOSITIVE POWER 1,549,364
           
      8. SHARED DISPOSITIVE POWER 0
           
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
    1,549,364
       
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES o
       
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
       
    2.88%
       
    12. TYPE OF REPORTING PERSON
       
    IA
     

    CUSIP No. 02155H200

     

    13G Page 4 of 9  

     

    1. NAME OF REPORTING PERSONS  
         
      Teachers Advisors, LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) o
        (b) o
         
    3. SEC USE ONLY  
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED  
    BY EACH REPORTING PERSON WITH:  
       
      5. SOLE VOTING POWER 171,273
           
      6. SHARED VOTING POWER 0
           
      7. SOLE DISPOSITIVE POWER 171,273
           
      8. SHARED DISPOSITIVE POWER 0
           
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
    171,273
       
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES o
       
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
       
    0.32%
       
    12. TYPE OF REPORTING PERSON
       
    IA
     

    CUSIP No. 02155H200

     

    13G Page 5 of 9  

     

    Item 1(a). NAME OF ISSUER:

     

    Altimmune Inc.

     

    Item 1(b). ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES:

     

    910 Clopper Road Suite 201S

    Gaithersburg, MD 20878

    United States

     

    Items 2(a)-2(c). NAME, ADDRESS OF PRINCIPAL BUSINESS OFFICE, AND CITIZENSHIP OF PERSONS FILING:

     

    Nuveen Asset Management, LLC (“NAM”)

    333 W. Wacker Drive

    Chicago, IL 60606

    Citizenship: Delaware

     

    TIAA-CREF Investment Management, LLC (“TCIM”)

    730 Third Avenue

    New York, NY 10017-3206

    Citizenship: Delaware

     

    Teachers Advisors, LLC (“TAL”)

    730 Third Avenue

    New York, NY 10017-3206

    Citizenship: Delaware

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:

     

    Common Stock

     

    Item 2(e). CUSIP NUMBER:  02155H200
     

    CUSIP No. 02155H200

     

    13G Page 6 of 9  

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b), OR 13d-2(b) or (c), CHECK WHETHER THE PERSON FILING IS A:

     

    NAM

     

    (a) o Broker or dealer registered under Section 15 of the Exchange Act.
         
    (b) o Bank as defined in Section 3(a)(6) of the Exchange Act.
         
    (c) o Insurance Company as defined in Section 3(a)(19) of the Exchange Act.
         
    (d) o Investment Company registered under Section 8 of the Investment Company Act of 1940.
         
    (e) x An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
         
    (f) o An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
         
    (g) o A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
         
    (h) o A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
         
    (i) o A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940.
         
    (j) o Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

     

    TCIM

     

    (a) o Broker or dealer registered under Section 15 of the Exchange Act.
         
    (b) o Bank as defined in Section 3(a)(6) of the Exchange Act.
         
    (c) o Insurance Company as defined in Section 3(a)(19) of the Exchange Act.
         
    (d) o Investment Company registered under Section 8 of the Investment Company Act of 1940.
         
    (e) x An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).  
         
    (f) o An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
         
    (g) o A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
         
    (h) o A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
         
    (i) o A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940.
         
    (j) o Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

     

    TAL

     

    (a) o Broker or dealer registered under Section 15 of the Exchange Act.
         
    (b) o Bank as defined in Section 3(a)(6) of the Exchange Act.
         
    (c) o Insurance Company as defined in Section 3(a)(19) of the Exchange Act.
         
    (d) o Investment Company registered under Section 8 of the Investment Company Act of 1940.
     

    CUSIP No. 02155H200

     

    13G Page 7 of 9  

     

    (e) x An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).  
         
    (f) o An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
         
    (g) o A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
         
    (h) o A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
         
    (i) o A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940.
         
    (j) o Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

     

    If this statement is filed pursuant to Rule 13d-1(c), check this box. o

     

    Item 4. OWNERSHIP

     

      (a) Aggregate amount beneficially owned:  1,727,316 (See Exhibit A attached)
           
      (b) Percent of class: 3.21%
           
      (c) Number of shares as to which person has:

     

      NAM TCIM TAL  
             
    Sole Voting Power: 6,679 1,549,364 171,273  
             
    Shared Voting Power: 0 0 0  
             
    Sole Dispositive Power: 6,679 1,549,364 171,273  
             
    Shared Dispositive Power: 0 0 0  

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o.

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
       
      See Exhibit A attached
       
    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
       
      Not Applicable
     

    CUSIP No. 02155H200

     

    13G Page 8 of 9  

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
       
      Not Applicable
       
    Item 9. NOTICE OF DISSOLUTION OF GROUP.
       
      Not Applicable
       
    Item 10. CERTIFICATIONS.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with nomination under §240.14a-11

     

    SIGNATURE.

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 14, 2024

     

      NUVEEN ASSET MANAGEMENT, LLC
       
      By:  /s/ Erik Mogavero
      Erik Mogavero
      Managing Director
      Head of Affiliate Compliance
       
      TIAA-CREF INVESTMENT MANAGEMENT, LLC
      By:  /s/ Stuart R. Brunet
      Stuart Brunet, Managing Director,
      Chief Compliance Officer
       
      TEACHERS ADVISORS, LLC
       
      By:  /s/ Stuart R. Brunet
      Stuart Brunet, Managing Director,
      Chief Compliance Officer
     

    CUSIP No. 02155H200

     

    13G Page 9 of 9  

     

    EXHIBIT A

     

    ITEM 6. OWNERSHIP.

     

    Nuveen Asset Management, LLC (“NAM”), is a registered investment adviser affiliated with TCIM and TAL. NAM may be deemed to be a beneficial owner of 6,679 shares of Issuer’s common stock. TIAA-CREF Investment Management, LLC (“TCIM”) is the investment adviser to the College Retirement Equities Fund (“CREF”), a registered investment company, and may be deemed to be a beneficial owner of 1,549,364 shares of Issuer’s common stock owned by CREF. Teachers Advisors, LLC (“TAL”) is the investment adviser to three registered investment companies, TIAA-CREF Funds (“Funds”), TIAA-CREF Life Funds (“Life Funds”), and TIAA Separate Account VA-1 (“VA-1”), as well as one or more separately managed accounts of Advisors (collectively, the “Separate Accounts”), and may be deemed to be a beneficial owner of 171,273 shares of Issuer’s common stock owned separately by Funds, Life Funds, VA-1, and/or the Separate Accounts.. These shares were acquired in the ordinary course of business, and not with the purpose or effect of changing or influencing control of the Issuer.

     
    Get the next $ALT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALT

    DatePrice TargetRatingAnalyst
    7/10/2025$1.00Sell
    Goldman
    2/28/2025Mkt Perform
    William Blair
    1/8/2025$18.00Buy
    Stifel
    11/12/2024$26.00Buy
    UBS
    4/29/2024Buy → Neutral
    Guggenheim
    1/24/2024$13.00Neutral
    Goldman
    3/22/2023$20.00 → $6.00Buy → Neutral
    Goldman
    12/1/2022$20.00Buy
    Goldman
    More analyst ratings

    $ALT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Sohn Catherine A.

    4 - Altimmune, Inc. (0001326190) (Issuer)

    9/29/25 4:21:00 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Durso Jerome Benedict

    4 - Altimmune, Inc. (0001326190) (Issuer)

    9/29/25 4:20:03 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Lawver Teri L

    4 - Altimmune, Inc. (0001326190) (Issuer)

    9/29/25 4:19:09 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    SEC Filings

    View All

    Altimmune Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Altimmune, Inc. (0001326190) (Filer)

    9/25/25 4:07:15 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Altimmune Inc.

    DEF 14A - Altimmune, Inc. (0001326190) (Filer)

    8/15/25 4:11:17 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Altimmune Inc.

    10-Q - Altimmune, Inc. (0001326190) (Filer)

    8/12/25 10:15:21 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Sohn Catherine A. bought $5,784 worth of shares (1,000 units at $5.78) (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    3/18/25 4:15:22 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Weaver Gregory L bought $51,996 worth of shares (10,000 units at $5.20) (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    3/14/25 7:27:34 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide

    Seasoned clinical leader to oversee Phase 3 development of pemvidutide in MASH Dr. Arbet-Engels has led late-stage development, regulatory approvals and commercial launches for multiple successful franchises GAITHERSBURG, Md., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the appointment of Christophe Arbet-Engels, MD, PhD as Chief Medical Officer, effective October 1, 2025. Dr. Arbet-Engels joins the Company with more than 30 years of experience spanning industry, academia and private practice, and will lead the ongoing c

    9/29/25 7:30:11 AM ET
    $ALT
    $XFOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Altimmune to Participate in Two Upcoming Investor Conferences

    GAITHERSBURG, Md., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company's management team will participate and be available for 1x1 meetings at the following investor conferences: Stifel 2025 Virtual Cardiometabolic ForumTuesday, September 30, 2025Fireside Chat at 10:30 a.m. Eastern Time H.C. Wainwright Liver Disease Virtual ConferenceTuesday, October 21, 2025Fireside Chat at 7:00 a.m. Eastern Time The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.

    9/23/25 7:30:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer

    GAITHERSBURG, Md., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the appointment of Linda M. Richardson to the role of Chief Commercial Officer, effective September 16, 2025. Ms. Richardson joins the Company with more than 30 years of experience in sales and marketing, commercial, corporate and business development across a range of therapeutic areas, including metabolic disease, hepatology, cardiovascular and addiction medicine. During her career, she has led multiple product launches, built successful commercial franchises

    9/15/25 7:30:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman resumed coverage on Altimmune with a new price target

    Goldman resumed coverage of Altimmune with a rating of Sell and set a new price target of $1.00

    7/10/25 8:47:17 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    William Blair initiated coverage on Altimmune

    William Blair initiated coverage of Altimmune with a rating of Mkt Perform

    2/28/25 7:17:56 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel initiated coverage on Altimmune with a new price target

    Stifel initiated coverage of Altimmune with a rating of Buy and set a new price target of $18.00

    1/8/25 7:32:53 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    Leadership Updates

    Live Leadership Updates

    View All

    Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide

    Seasoned clinical leader to oversee Phase 3 development of pemvidutide in MASH Dr. Arbet-Engels has led late-stage development, regulatory approvals and commercial launches for multiple successful franchises GAITHERSBURG, Md., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the appointment of Christophe Arbet-Engels, MD, PhD as Chief Medical Officer, effective October 1, 2025. Dr. Arbet-Engels joins the Company with more than 30 years of experience spanning industry, academia and private practice, and will lead the ongoing c

    9/29/25 7:30:11 AM ET
    $ALT
    $XFOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer

    GAITHERSBURG, Md., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the appointment of Linda M. Richardson to the role of Chief Commercial Officer, effective September 16, 2025. Ms. Richardson joins the Company with more than 30 years of experience in sales and marketing, commercial, corporate and business development across a range of therapeutic areas, including metabolic disease, hepatology, cardiovascular and addiction medicine. During her career, she has led multiple product launches, built successful commercial franchises

    9/15/25 7:30:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Altimmune Board of Directors Appoints Jerry Durso as Chairman

    Appointment recognizes Mr. Durso's extensive commercial expertise as Altimmune prepares for Phase 3 development of pemvidutide in MASH Mitchel Sayare, Ph.D., to remain on the Board as Independent Director GAITHERSBURG, Md., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that its Board of Directors has appointed Jerry Durso as Chairman, effective August 12, 2025. Mr. Durso succeeds Mitchel Sayare, Ph.D., who will continue to serve on the Board as an Independent Director. The leadership transition is part of the Board's

    8/11/25 7:30:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Altimmune Inc.

    SC 13G/A - Altimmune, Inc. (0001326190) (Subject)

    11/14/24 11:58:56 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Altimmune Inc.

    SC 13G/A - Altimmune, Inc. (0001326190) (Subject)

    10/17/24 11:16:51 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Altimmune Inc.

    SC 13G/A - Altimmune, Inc. (0001326190) (Subject)

    10/16/24 4:21:16 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    Financials

    Live finance-specific insights

    View All

    Altimmune Announces Second Quarter 2025 Financial Results and Business Update

    Positive data from the IMPACT Phase 2b trial reinforces the potential for pemvidutide to be a highly differentiated MASH therapy Pemvidutide is the first product candidate to achieve statistically significant MASH resolution and weight loss at 24 weeks New data from the IMPACT trial demonstrates potentially class-leading improvements in corrected T1 (cT1), an important marker of liver inflammation and fibrosis End-of-Phase 2 Meeting with FDA expected in Q4 2025 Cash, cash equivalents and short-term investments of $183.1 million as of June 30, 2025 Webcast to be held today, August 12, 2025, at 8:30 a.m. ET GAITHERSBURG, Md., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:A

    8/12/25 7:00:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025

    GAITHERSBURG, Md., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2025 financial results on Tuesday, August 12, 2025. Altimmune management will host a conference call at 8:30 am E.T. on August 12 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor R

    8/5/25 7:30:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH

    First product candidate to demonstrate significant MASH effects and weight loss at 24 weeks Trial met its primary endpoint with statistically significant MASH resolution without worsening of fibrosis in up to 59.1% of participants in an ITT analysis Fibrosis improvement without worsening of MASH in up to 34.5% of participants in an ITT analysis Supplemental AI-based analysis demonstrated statistically significant reductions in liver fibrosis at 24 weeks Weight loss of up to 6.2% at 24 weeks with no plateauing Potentially best-in-class tolerability, with less than 1% treatment discontinuations due to adverse events in pemvidutide-treated participants Conference call to be held on June 2

    6/26/25 7:00:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care